ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

por Brett, Jamie O., Spring, Laura M., Bardia, Aditya, Wander, Seth A.
Publicado 2021

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

por Cornell, Liam, Wander, Seth A., Visal, Tanvi, Wagle, Nikhil, Shapiro, Geoffrey I.
Publicado 2019

Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging...

por Lloyd, Maxwell R., Wander, Seth A., Hamilton, Erika, Razavi, Pedram, Bardia, Aditya
Publicado 2022

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

por Wander, Seth A, O’Brien, Neil, Litchfield, Lacey M, O’Dea, Declan, Morato Guimaraes, Claudia, Slamon, Dennis J, Goel, Shom
Publicado 2022

p27 transcriptionally coregulates cJun to drive programs of tumor progression

por Yoon, Hyunho, Kim, Minsoon, Jang, Kibeom, Shin, Miyoung, Besser, Alexandra, Xiao, Xue, Zhao, Dekuang, Wander, Seth A., Briegel, Karoline, Morey, Lluis, Minn, Andy, Slingerland, Joyce M.
Publicado 2019

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy

por Wander, Seth A., Zhao, Dekuang, Besser, Alexandra H., Hong, Feng, Wei, Jianqin, Ince, Tan A., Milikowski, Clara, Bishopric, Nanette H., Minn, Andy J., Creighton, Chad J., Slingerland, Joyce M.
Publicado 2013

Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy

por Wander, Seth A., Zhao, Dekuang, Besser, Alexandra H., Hong, Feng, Wei, Jianqin, Ince, Tan A., Milikowski, Clara, Bishopric, Nanette H., Minn, Andy J., Creighton, Chad J., Slingerland, Joyce M.
Publicado 2016

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer

por Hanna, Paul E., Strohbehn, Ian A., Moreno, Daiana, Harden, Destiny, Seethapathy, Rituvanthikaa, Sawtell, Rani, Wang, Qiyu, Ouyang, Tianqi, Katz-Agranov, Nurit, Dinulos, James, Wander, Seth A., Gupta, Shruti, Sise, Meghan E.
Publicado 2023

HGAL inhibits lymphoma dissemination by interacting with multiple cytoskeletal proteins

por Jiang, Xiaoyu, Lu, XiaoQing, Gentles, Andrew J., Zhao, Dekuang, Wander, Seth A., Zhang, Yu, Natkunam, Yasodha, Slingerland, Joyce, Reis, Isildinha M., Rabinovich, Brian, Abdulreda, Midhat H., Moy, Vincent T., Lossos, Izidore S.
Publicado 2021

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses

por Azzam, Diana J, Zhao, Dekuang, Sun, Jun, Minn, Andy J, Ranganathan, Prathibha, Drews-Elger, Katherine, Han, Xiaoqing, Picon-Ruiz, Manuel, Gilbert, Candace A, Wander, Seth A, Capobianco, Anthony J, El-Ashry, Dorraya, Slingerland, Joyce M
Publicado 2013

Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series

por Brett, Jamie O, Ritterhouse, Lauren L, Newman, Erik T, Irwin, Kelly E, Dawson, Megan, Ryan, Lianne Y, Spring, Laura M, Rivera, Miguel N, Lennerz, Jochen K, Dias-Santagata, Dora, Ellisen, Leif W, Bardia, Aditya, Wander, Seth A
Publicado 2022

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor...

por Gerratana, Lorenzo, Davis, Andrew A., Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L., Shah, Ami N., Dai, Charles S., Reduzzi, Carolina, D’Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A., Gradishar, William J., Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X., Bardia, Aditya, Cristofanilli, Massimo
Publicado 2023

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer

por Denault, Elyssa, Nakajima, Erika, Naranbhai, Vivek, Hutchinson, Jennifer A., Mortensen, Lindsey, Neihoff, Elizabeth, Barabell, Caroline, Comander, Amy, Juric, Dejan, Kuter, Irene, Mulvey, Theresa, Peppercorn, Jeffrey, Rosenstock, Aron S., Shin, Jennifer, Vidula, Neelima, Wander, Seth A., Moy, Beverly, Ellisen, Leif W., Isakoff, Steven J., Iafrate, A. John, Gainor, Justin F., Bardia, Aditya, Spring, Laura M.
Publicado 2022

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

por Fathi, Amir T., Wander, Seth A., Blonquist, Traci M., Brunner, Andrew M., Amrein, Philip C., Supko, Jeffrey, Hermance, Nicole M., Manning, Amity L., Sadrzadeh, Hossein, Ballen, Karen K., Attar, Eyal C., Graubert, Timothy A., Hobbs, Gabriela, Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Silver, Regina, Foster, Julia, Bergeron, Meghan, Ramos, Aura Y., Som, Tina T., Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., Chen, Yi-Bin
Publicado 2017